One of the biggest players in healthcare education is teaming up with Google to teach both healthcare students and practicing professionals how to better use AI.

Adtalem Global Education rolled out a new credentials program in partnership with Google Cloud to familiarize doctors and nurses with the ins and outs of the generative AI technology that’s been flooding the industry.

The program will debut next year across all of Adtalem’s for-profit universities, which collectively reach 91,000 students. Coursework will cover “AI applications in clinical practice, ethical considerations, patient safety protocols, and hands-on experience with healthcare-specific AI tools commonly used across hospital systems and clinical practices,” per the announcement. Google’s Gemini model and Vertex agent builder will also be integrated into the curriculum.

In demand. The program aims to fill a gap, according to Michael Betz, chief digital officer at Adtalem and president of Adtalem-owned Walden University. In the past six to nine months, in particular, Adtalem’s hundreds of healthcare partners have been pushing for talent that’s savvy about the various AI tools now in use in clinical practice, Betz told us. There’s been interest from students too, who don’t want to be left behind, he said.

“A big part of our strategy here at Adtalem is to make sure that our graduates are able to not just be fluent with AI, but help in an effective and ethical way to lead that change in healthcare systems,” Betz said.

See more on how the partnership will work here.—PK

GLP-1s are a cash cow for the drug industry, with profits rising higher than ever imagined.

Despite concerns over affordability and side effects, in May, analysts at Morgan Stanley Research predicted the global obesity drug market could peak at $150 in 2035, up from the firm’s previous forecast of $105 billion.

Drug companies are scrambling for the biggest piece of that profitable pie. Whether it be looking into how to create oral versions of these injectable drugs or battling to acquire other drugmakers—cough, cough, Pfizer and Novo Nordisk—they’re all racing to stay ahead of the competition.

“We are literally just scratching the surface of global [obesity] treatment here,” Chair and CEO of Eli Lilly David Ricks said in an Oct. 30 earnings call. “There really is a tremendous opportunity to reach tens or even hundreds of millions of more people in the coming years, and that’s our goal.”

Keeping up?!—CC

The FDA gets 2+ million reports of deaths, injuries, and malfunctions associated with medical devices every year.

When these events make up a trend, the device manufacturer and FDA issue a recall for that device, ranging from Class III (least dangerous) to Class I (most dangerous). If you’re a medical provider, you must then follow the manufacturer or FDA’s instructions, whether they tell you to tweak how you use a device or stop using it altogether.

But with so many recalls, it can be hard to keep track! That’s where we come in. We keep you informed on some recent Class I recalls here in our monthly series.

Welcome to October’s Recall Roundup.

Abbott’s advice. Abbott has changed up its catheter packaging design and provided users with additional guidance after reports of some catheter tips detaching while being removed from packaging.

See the full list here.—CC

More than two years after Roe v. Wade fell, the patchwork of abortion access across the US is more complicated than ever. Ten states put reproductive rights directly on the ballot last year, with mixed results—and ongoing legal challenges are reshaping care again. For providers, policymakers, and patients alike, the uncertainty has real consequences. Here’s how state laws, federal reviews, and shifting access are redefining reproductive care in 2025.

Real jobs, shared through real communities. CollabWORK brings opportunities directly to Healthcare Brew readers—no mass postings, no clutter, just roles worth seeing. Click here to view the full job board.